The sales of biopharmaceuticals and biotherapy from only Humira, Remicade, and Enbrel are over $18 billion in US in 2015. Protein therapy is expected to make about $250 billion in savings for US over the next 10 years. Manufacturing biopharmaceuticals in a cost effective and reliable route becomes a major challenge for meeting the rapidly growing demands of protein-based medicines. Crystallisation of proteins (like insulin) as one-step operation is more efficient, leading to advantages of stability storage, formulation and drug delivery.
This PhD project aims to develop innovative methods on (bio)crystalisation of (bio)pharmaceuticals, including macromolecules (proteins, virus, and etc) and small molecules. The successful project will lead to a revolution in application of 3D printing templates with different surface properties, including striped hydro-phobic/philic style with hollow/multi-porous structured particles or tubes on accelerating crystallisation and purification of proteins.
The ideal student would have an interest in the medical application of additive manufacturing and possess strong mechanical and mechatronics skills.
Applicants should have, or expect to achieve, at least a 2:1 Honours degree (or equivalent) in Mechanical Engineering, Chemical Engineering, Chemistry or a related subject.
A relevant Master’s degree and/or experience in one or more of the following will be an advantage: additive manufacturing, (bio) separation and interdisciplinary technologies.